Study of the effect of administration of finasteride in benign prostatic hyperplasia patients on bleeding during and after transurethral resection of prostate
Abstract
Aim of the study:
The aim of this study is to study the effect of administration of finasteride in benign prostatic hyperplasia patients on bleeding during and after transurethral resection of prostate.
Introduction:
Transurethral resection of the prostate is considered the standard technique for patients with moderate or severe lower urinary tract symptoms related to
benign prostatic hyperplasia (BPH). Pathologically BPH is characterized by increased proliferation of stromal and acinar cells, sustained by increased vascularization
(neoangiogenesis). Recent studies have also shown that finasteride reduces angiogenesis and prostatic bleeding associated with BPH. Reducing the volume as a final step in reducing neoangiogenesis could thus represent a fundamental
advance in limiting intra- and postoperative bleeding in patients undergoing transurethral resection of the prostate (TURP).
Materials and Methods:
Our study included 84 patients undergoing TURP between June 2021 and June 2022. Of the patients, 35 received pretreatment with finasteride while 49 did not undergo any pretreatment (control group). In all the patients we evaluated the degree of peri-surgical bleeding, intended as a
reduction in hemoglobin values in the 24 h following surgery.
Results and Conclusions:
In the group of patients
pretreated with finasteride(average age 66.3 years), blood loss, evaluated as a reduction in hemoglobin values, was minimal, and only one of the patients(2.8) required blood transfusion. Hemoglobin loss in the 24 h following surgery was 1.1% .In the control group (average age 65.8 years), 5 patients (10.2%) required blood transfusion. The loss of hemoglobin was 2.1%. Finasteride, therefore, seems to play fundamental role in the pretreatment of TURP patients, since by educing dihydrotestosterone synthesis, it interacts with endothelial growth factors, thus reducing angiogenesis and preventing bleeding.
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.